Loading...
In trials of new drugs for prostate cancer, demonstrating reduced mortality is challenging because even patients with poor-risk, locally advanced disease can have prolonged survival. To shorten the duration of these trials, surrogate endpoints for disease-specific survival are required. To evaluate distant metastasis and treatment failure as two potential surrogates, investigators conducted a secondary analysis of data from the Radiation Therapy and Oncology Group (RTOG) 92-02 trial involving patients with locally advanced prostate cancer who received neoadjuvant therapy and androgen-deprivation therapy (ADT) plus radiation therapy and then either 2 years of additional ADT or no additional therapy (JW Oncol Hematol Jun 17 2008).
The research…